M Debled
Overview
Explore the profile of M Debled including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
592
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Penault-Llorca F, Dalenc F, Chabaud S, Cottu P, Allouache D, Cameron D, et al.
ESMO Open
. 2024 May;
9(5):103443.
PMID: 38692082
Background: The purpose of this study was to evaluate the prognostic value of the multigene EndoPredict test in prospectively collected data of patients screened for the randomized, double-blind, phase III...
2.
Frenel J, Lusque A, Delaloge S, Ferrero J, Bachelot T, Desmoulins I, et al.
Br J Cancer
. 2023 Apr;
128(11):2072-2080.
PMID: 37012318
Background: Efficacy of endocrine therapy in HR+/HER2- metastatic breast cancer could differ depending on the presence of BRCA1/2 germline mutation. Methods: The ESME metastatic breast cancer platform (NCT03275311) is a...
3.
Blaye C, Darbo E, Debled M, Brouste V, Velasco V, Pinard C, et al.
ESMO Open
. 2022 Jun;
7(4):100502.
PMID: 35759853
Background: When triple-negative breast cancer (TNBC) patients have residual disease after neoadjuvant chemotherapy (NACT), they have a high risk of metastatic relapse. With immune infiltrate in TNBC being prognostic and...
4.
Gaillard T, Carton M, Mailliez A, Desmoulins I, Mouret-Reynier M, Petit T, et al.
Eur J Cancer
. 2022 Mar;
166:311-312.
PMID: 35314113
No abstract available.
5.
Bringuier M, Carton M, Levy C, Patsouris A, Pasquier D, Debled M, et al.
Breast Cancer Res Treat
. 2022 Jan;
191(3):577-587.
PMID: 34984582
Purpose: Older cancer patients are underrepresented in clinical trials. We aimed to evaluate the enrollment of older women aged 70 years old (yo) or over with metastatic breast cancer (MBC)...
6.
Gaillard T, Carton M, Mailliez A, Desmoulins I, Mouret-Reynier M, Petit T, et al.
Eur J Cancer
. 2021 Oct;
158:181-188.
PMID: 34689042
Introduction: The estimated rate of de novo metastatic breast cancer (dnMBC) at the time of diagnosis is between 5 to 12%. International guidelines recommend metastatic work-up (MWU) only in women...
7.
Carausu M, Carton M, Darlix A, Pasquier D, Leheurteur M, Debled M, et al.
ESMO Open
. 2021 May;
6(3):100150.
PMID: 33984675
Background: Leptomeningeal metastasis (LM) is a rare complication of metastatic breast cancer (MBC), with high morbidity/mortality rates. Our study aimed to describe the largest-to-date real-life population of MBC patients treated...
8.
Grinda T, Antoine A, Jacot W, Blaye C, Cottu P, Dieras V, et al.
ESMO Open
. 2021 Apr;
6(3):100114.
PMID: 33895695
Background: Treatment strategies for metastatic breast cancer (MBC) have made great strides over the past 10 years. Real-world data allow us to evaluate the actual benefit of new treatments. ESME...
9.
Gougis P, Carton M, Tchokothe C, Campone M, Dalenc F, Mailliez A, et al.
Breast
. 2019 Nov;
49:17-24.
PMID: 31675683
Purpose: The Time to First Metastatic Recurrence (TFMR) could be considered as an indirect reflection of the tumour growth kinetics which plays an important role in cancer. Molecular subtypes such...
10.
Jacquet E, Lardy-Cleaud A, Pistilli B, Franck S, Cottu P, Delaloge S, et al.
Eur J Cancer
. 2018 Apr;
95:93-101.
PMID: 29655061
Background: For hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2-) negative metastatic breast cancer (MBC), international guidelines recommend endocrine therapy as first-line treatment, except in case of 'visceral...